Meningococcal vaccine recommendations, United States, 2023

Recommended meningococcal vaccines for persons at increased risk for meningococcal disease due to serogroups A, B, C, W, or Y and who are due for both meningococcal A, C, W, and Y vaccine and meningococcal B vaccine. Notes: (1) MenACWY products are interchangeable; the same vaccine product is recommended, but not required, for all doses. (2) Different manufacturers’ MenB vaccines are not interchangeable. (3) To determine whether MenACWY and MenB are indicated based on a person’s risk factors and timing of any previous meningococcal vaccines, clinicians should see previously published recommendations (Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69[9]:1-41). (4) If MenB was received previously, but the vaccine manufacturer is not known, the series must be restarted with any licensed product to ensure completion of the series using products from a single manufacturer (Mbaeyi et al 2020). (5) If MenB-FHbp was received previously, MenACWY-TT/MenB-FHbp may be used provided the person has not received MenACWY-TT/MenB-FHbp previously or 6 or more months have passed since the previous dose of MenACWY-TT/MenB-FHbp.

Abbreviations: MenACWY = quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccine; MenACWY-TT/MenB-FHbp = Penbraya (Pfizer Inc) pentavalent (serogroups A, B, C, W, and Y) meningococcal vaccine; MenB-FHbp = Trumenba (Pfizer Inc) serogroup B meningococcal vaccine; MenB-4C = Bexsero (GSK) serogroup B meningococcal vaccine.

(Source: Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2024;73[15]:345-50. Public domain.)